Pancreatic ductal adenocarcinoma (PDA) is an unusually lethal disease with the highest 1-year and 5- year mortality rates of any cancer. An inability to detect the disease early together with multiple mechanisms of intrinsic resistance to chemical and radiotherapies contribute to the extreme lethality of PDA. Compounding the challenge in developing effective targeted therapies against pancreas cancer is the high degree of both numerical (aneuploidy) and structural (non-reciprocal translocations) chromosomal instability. The robust fibroinflammatory response, or desmoplasia, that accompanies and chronicles disease progression presents additional challenges to treating the disease, while also providing novel potential targets and approaches to combating PDA. We have recently characterized a number of critical elements of the desmoplastic reaction in pancreas cancer and the mechanisms by which these components promote and sustain nascent neoplasms. These components include tumor- associated macrophages, stromal fibroblasts and multiple types of immunosuppressive cells that invade and surround precursor ductal lesions from the earliest stages of preinvasive disease;a dense stromal collagen and proteoglycan matrix that appears to suppress angiogenesis and compromise tumor vascularity;and extremely high intratumoral fluid pressures. Thus, the delivery, diffusion and convection of small molecules are all critically limited by the stromal environment and together these various factors conspire to create a sanctuary for pancreas cancer progression. In this proposal, we will investigate first the ability of distinct interventions to disrupt the stromal matrix and improve perfusion in pancreas cancer to enhance the delivery and efficacy of chemotherapeutic agents. We will also test the ability of combining strategies directed against the stromal and epithelial compartments to make a clinically significant impact against this lethal disease.
Pancreas cancer kills every patient it afflicts and is now the fourth leading cause of cancer-related deaths in this country with a rising incidence and unabated mortality. We have developed genetically engineered animal models of pancreas cancer that have exposed unique points of vulnerability for the development of new treatments. We propose a systematic program of investigation to target the fibrotic stromal reaction in pancreas cancer as the basis for new treatment strategies against this highly resistant disease.
|Stromnes, Ingunn M; Hulbert, Ayaka; Pierce, Robert H et al. (2017) T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 5:978-991|
|Whittle, Martin C; Hingorani, Sunil R (2017) Runx3 and Cell Fate Decisions in Pancreas Cancer. Adv Exp Med Biol 962:333-352|
|Whittle, Martin C; Hingorani, Sunil R (2017) Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer J 23:326-332|
|DuFort, Christopher C; Hingorani, Sunil R (2016) Tension and Transformation in Pancreas Cancer: Can Phenotype Break Free from the Chrysalis of Genotype? Cancer Cell 29:780-782|
|DuFort, Christopher C; DelGiorno, Kathleen E; Hingorani, Sunil R (2016) Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. Gastroenterology 150:1545-1557.e2|
|DuFort, Christopher C; DelGiorno, Kathleen E; Carlson, Markus A et al. (2016) Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. Biophys J 110:2106-19|
|Whittle, Martin C; Hingorani, Sunil R (2016) RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. Mol Cell Oncol 3:e1076588|
|Whittle, Martin C; Hingorani, Sunil R (2015) Disconnect between EMT and metastasis in pancreas cancer. Oncotarget 6:30445-6|
|Stromnes, Ingunn M; Schmitt, Thomas M; Hulbert, Ayaka et al. (2015) T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell 28:638-652|
|Hingorani, Sunil R (2015) Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy. Cancer Cell 28:151-3|
Showing the most recent 10 out of 20 publications